MARC was founded on pioneering scientific research led by Dr David Wilkinson and Professor Clive Holmes (as seen in the photo above). Their early work produced a landmark discovery: in a post-mortem study, the first amyloid (Abeta 42) vaccine was shown to clear amyloid plaques from the brains of people with Alzheimer’s disease. This breakthrough significantly advanced global understanding of the causes of Alzheimer’s and helped shape the development of future dementia treatments.

​

Building on this foundation, MARC played a key role in the first clinical trials of cholinesterase inhibitors - treatments that are now widely known as donepezil, rivastigmine, galantamine and memantine. These therapies remain central to clinical practice today and continue to support people living with Alzheimer’s disease around the world.

​

Over the years, our scientific contributions have expanded across multiple fields, from genetics to the study of inflammation in dementia and its connections to conditions such as rheumatoid arthritis and gum disease. We have extensive experience delivering trials that evaluate antibody, anti-inflammatory and anti-diabetic agents, helping to shape new possibilities for treatment.

​

Our commitment to dementia research has also included exploring therapeutic and person-centered approaches such as aromatherapy, music therapy and nostalgia-based interventions - recognising the importance of improving quality of life alongside clinical outcomes.

​

Today, MARC continues to deliver the latest clinical trials testing amyloid antibodies, the first disease-modifying therapies shown to slow the progression of Alzheimer’s disease. Our work reflects the same passion that inspired our earliest research: a dedication to advancing medicine and healthcare, and a determination to contribute to a future where dementia can be prevented, treated, or cured.